Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial.

Contraceptive implant Drug concentrations Drug interactions Efavirenz Levonorgestrel

Journal

Contraception: X
ISSN: 2590-1516
Titre abrégé: Contracept X
Pays: United States
ID NLM: 101767748

Informations de publication

Date de publication:
2020
Historique:
received: 28 12 2019
revised: 18 05 2020
accepted: 19 05 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 29 12 2020
Statut: epublish

Résumé

Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz. We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point. The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46-0.79] at 1 month to 0.27 (90% CI 0.12-0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations < 180 pg/mL (the previously suggested minimum threshold concentration for efficacy). Efavirenz users had lower levonorgestrel concentrations than non-efavirenz users, and one third of our concomitant efavirenz and levonorgestrel implant users had concentrations < 180 pg/mL. Continued evaluation of the contraceptive efficacy of the levonorgestrel implant may be needed for efavirenz users. Among 42 Malawian women using the levonorgestrel implant for contraception, women who were taking the antiretroviral efavirenz had lower serum levonorgestrel concentrations than women who were not taking efavirenz. However, none of the women who were taking efavirenz became pregnant over 60 women-years of follow-up.

Identifiants

pubmed: 33364598
doi: 10.1016/j.conx.2020.100027
pii: S2590-1516(20)30010-1
pmc: PMC7752709
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100027

Informations de copyright

© 2020 The Authors.

Références

Br J Clin Pharmacol. 2006 Feb;61(2):148-54
pubmed: 16433869
Lancet HIV. 2015 Nov;2(11):e474-82
pubmed: 26520927
Eur J Clin Pharmacol. 2014 Apr;70(4):379-89
pubmed: 24390631
Glob Health Sci Pract. 2018 Mar 30;6(1):17-39
pubmed: 29559495
Contraception. 1975 Sep;12(3):279-98
pubmed: 1164847
AIDS. 2017 Apr 24;31(7):917-952
pubmed: 28060009
Clin Pharmacol Ther. 2017 Sep;102(3):529-536
pubmed: 28187506
Contraception. 2000 Mar;61(3):187-94
pubmed: 10827332
AIDS Care. 2015;27(4):489-98
pubmed: 25367269
J Infect Dis. 2012 Nov;206(9):1453-61
pubmed: 22927450
Sex Transm Infect. 2020 Jun 11;:
pubmed: 32527793
AIDS Care. 2016 Aug;28(8):1027-34
pubmed: 26877194
AIDS. 2019 Nov 1;33(13):1995-2004
pubmed: 31306173
Contraception. 2011 May;83(5):397-404
pubmed: 21477680
AIDS. 2014 Mar 13;28(5):791-3
pubmed: 24401645
Clin Infect Dis. 2016 Mar 15;62(6):675-682
pubmed: 26646680
PLoS One. 2015 Mar 26;10(3):e0121039
pubmed: 25811849
AIDS. 2009 Nov;23 Suppl 1:S7-S17
pubmed: 20081391
Contemp Clin Trials. 2017 Jan;52:27-34
pubmed: 27836505

Auteurs

Jennifer H Tang (JH)

University of North Carolina at Chapel Hill, 111 Mason Farm Road, CB #7577; Chapel Hill, NC, 27599-7577, USA.
UNC Project Malawi, 100 Mzimba Drive, Private Bag A104, Lilongwe, Malawi.

Nicole L Davis (NL)

US Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, 30329, USA.

Amanda H Corbett (AH)

University of North Carolina at Chapel Hill, 111 Mason Farm Road, CB #7577; Chapel Hill, NC, 27599-7577, USA.

Lameck Chinula (L)

University of North Carolina at Chapel Hill, 111 Mason Farm Road, CB #7577; Chapel Hill, NC, 27599-7577, USA.
UNC Project Malawi, 100 Mzimba Drive, Private Bag A104, Lilongwe, Malawi.

Mackenzie L Cottrell (ML)

University of North Carolina at Chapel Hill, 111 Mason Farm Road, CB #7577; Chapel Hill, NC, 27599-7577, USA.

Yasaman Zia (Y)

US Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, 30329, USA.

Gerald Tegha (G)

UNC Project Malawi, 100 Mzimba Drive, Private Bag A104, Lilongwe, Malawi.

Frank Z Stanczyk (FZ)

University of Southern California, Keck School of Medicine, Reproductive Endocrine Research Laboratory, 1321 N. Mission Road, Los Angeles, CA, 90033, USA.

Stacey Hurst (S)

US Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, 30329, USA.

Mina C Hosseinipour (MC)

University of North Carolina at Chapel Hill, 111 Mason Farm Road, CB #7577; Chapel Hill, NC, 27599-7577, USA.
UNC Project Malawi, 100 Mzimba Drive, Private Bag A104, Lilongwe, Malawi.

Lisa B Haddad (LB)

Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30322, USA.

Athena P Kourtis (AP)

US Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, 30329, USA.

Classifications MeSH